Apr 21, 2026
About Tenpoint Therapeutics Tenpoint Therapeutics is a global, commercial biotechnology company focused on developing groundbreaking treatments to improve vision in the aging eye. Our pipeline includes paradigm-shifting therapeutics for ophthalmic indications with significant unmet medical need, including presbyopia, cataracts, and geographic atrophy. Our lead product, YUVEZZI™, is the first and only dual-agent eye drop for the treatment of presbyopia in adults and was approved by the FDA on January 28, 2026. Presbyopia, the gradual loss of near vision that typically begins around age 45, affects about two billion people globally and 128 million people in the U.S. YUVEZZI™ is expected to be broadly commercially available in the U.S. in Q2 2026. Role Overview Reporting to the CEO, the Executive Assistant (EA) provides proactive, hands-on support for the day-to-day business activities of several C-suite Executives, including the CEO, CFO, and other executives and team members as...
Visus Therapeutics Inc.
NJ